Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Katharina Roltgen et al.
Summary: During the SARS-CoV-2 pandemic, different vaccines have been used globally. This study compares the antibodies generated by mRNA vaccines, infection, and other types of vaccines. It shows that mRNA vaccines result in a better antibody breadth against viral variants compared to infection. Infection leads to variant-specific antibodies, while mRNA vaccination imprints responses towards the original virus strain. mRNA vaccines also stimulate robust germinal centers in lymph nodes, enhancing the immune response.
Review
Infectious Diseases
Caifang Zheng et al.
Summary: A meta-analysis showed that COVID-19 vaccines have high efficacy in real-world settings, providing significant protection against SARS-CoV-2-related diseases. Fully vaccinated individuals had vaccine effectiveness of 89.1% against infection, 97.2% against hospitalization, 97.4% against ICU admission, and 99.0% against death.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Clinical Neurology
Carla Tortorella et al.
Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.
Article
Multidisciplinary Sciences
Peter B. Gilbert et al.
Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.
Article
Immunology
Marco Iannetta et al.
Summary: This study analyzed the cell-mediated immune responses in multiple sclerosis patients who received the mRNA vaccine, revealing differences in antibody levels and peripheral blood lymphocyte counts among patients on different drug treatments.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Matthew Gagne et al.
Summary: This study shows that both mRNA-1273 and mRNA-Omicron generate comparable immunity and protection after booster doses, and are able to neutralize the Omicron variant.
Article
Immunology
Chunfeng Li et al.
Summary: The BNT162b2 mRNA vaccine stimulates potent antibody and antigen-specific T cell responses, as well as enhanced innate responses after secondary immunization. Circulating IFN-gamma is mainly produced by natural killer cells and CD8(+) T cells in the draining lymph nodes. The CD8(+) T cell response is dependent on type I interferon-dependent MDA5 signaling.
Review
Medicine, General & Internal
Kai Wang et al.
Summary: This study evaluated the effectiveness of various COVID-19 vaccines against variants through a meta-analysis. The results showed that the current vaccines used globally can significantly prevent COVID-19 infection and restrict the spread of variants. The efficacy of two doses of vaccine was more pronounced compared to one dose, and mRNA vaccines were found to be the most effective against variants. It is important to consider the local prevalence of variants when selecting specific vaccines.
FRONTIERS IN MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Olga Kalinina et al.
Summary: This study investigated the levels of cytokines in patients with moderate and severe COVID-19 and found elevated levels of pro-inflammatory factors, chemokines, anti-inflammatory factors, and growth factors. Patients with severe disease had higher levels of FGF-2/FGF-basic, IL-1 beta, and IL-7 compared to healthy donors. Pneumonia lung injury was positively correlated with levels of EGF, IP-10, and MCP-3, and negatively correlated with IL-12 p40. Pro-inflammatory factors were negatively correlated with the frequency of circulating Th17-like cells and follicular Th cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Gisella Guerrera et al.
Summary: Development of long-lasting anti-SARS-CoV-2 T-cell responses is not impaired in ocrelizumab-treated pwMS.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Medicine, General & Internal
Xi Wu et al.
Summary: This meta-analysis evaluated the immune response to COVID-19 vaccines in patients with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study found that pwMS receiving anti-CD20 and sphingosine-1-phosphate receptor modulator (S1PRM) treatments had attenuated serologic response after full vaccination. No significant associations were found between other treatments and humoral response. As for T-cell response, no significant difference was found between pwMS on anti-CD20 and those without DMTs, while S1PRM was marginally associated with impaired cellular response.
Article
Virology
Federico Gobbi et al.
Summary: Individuals who previously contracted SARS-CoV-2 are expected to have a more rapid and sustained immune response to COVID-19 vaccines, with markedly higher titers of neutralizing antibodies compared to natural infection. A single dose of the vaccine may be sufficient to induce an effective response in previously infected individuals.
Review
Biochemistry & Molecular Biology
Daniela Ricci et al.
Summary: The vulnerability and unpredictability of humankind to SARS-CoV-2, coupled with its high transmissibility and tissue tropism, pose a major challenge in perpetuating the COVID-19 pandemic. However, researchers have the unique opportunity to study the immune response and its impact on disease severity, highlighting the role of innate immune cells, cytokines, and chemokines in shaping the outcome of SARS-CoV-2 infection.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Prabhu S. Arunachalam et al.
Summary: The study found that vaccination with the Pfizer-BioNTech mRNA vaccine can induce immune responses against neutralizing antibodies and CD4, CD8 T cells of SARS-CoV-2. Booster vaccines can significantly enhance innate immune responses, and different innate pathways associated with CD8 T cells and neutralizing antibodies have been identified.
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.
Article
Biochemistry & Molecular Biology
Sokratis A. Apostolidis et al.
Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.
Editorial Material
Biochemistry & Molecular Biology
Florian Krammer
Article
Biochemistry & Molecular Biology
Angela Choi et al.
Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.
Article
Cell Biology
Cristina Bergamaschi et al.
Summary: Early responses to vaccination play a crucial role in shaping both humoral and cellular protective immunity. This study characterizes cytokine and chemokine responses after the first and second dose of the BNT162b2 mRNA vaccine, highlighting the potential for biomarkers like IL-15 and IFN-gamma in predicting humoral immunity development. In previously COVID-19-infected individuals, a single vaccination can trigger strong cytokine induction and antibody responses similar to those seen in naive individuals upon booster vaccination, with implications for future public health recommendations.
Article
Microbiology
Martina Severa et al.
Summary: The study highlights the crucial role of pDC/type I IFN axis in defending against SARS-CoV-2 infection in COVID-19 patients, suggesting that a deeper understanding may aid in the development of new drug strategies and host-directed therapies. Moreover, the findings indicate that critically ill patients exhibit impaired type I IFN response and high levels of inflammatory cytokines and chemokines, leading to multi-organ failure.
Article
Medicine, General & Internal
Maria Pia Sormani et al.
Summary: This study found that anti-CD20 treatment and fingolimod in MS patients led to reduced humoral response to mRNA vaccines. mRNA-1273 vaccine resulted in significantly higher antibody levels compared to BNT162b2, suggesting it may be preferred for patients under certain treatments.
Article
Clinical Neurology
Anat Achiron et al.
Summary: The study found that after receiving the COVID-19 vaccine, MS patients who were either untreated or treated with cladribine showed a high level of protective humoral immunity, similar to healthy subjects. However, only a small percentage of MS patients treated with ocrelizumab and fingolimod developed a humoral immune response.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Article
Immunology
Martina Severa et al.
JOURNAL OF AUTOIMMUNITY
(2019)
Article
Clinical Neurology
Elena Giacomini et al.
MULTIPLE SCLEROSIS JOURNAL
(2018)
Article
Clinical Neurology
Elena Giacomini et al.
MULTIPLE SCLEROSIS JOURNAL
(2018)
Review
Biotechnology & Applied Microbiology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY
(2018)
Article
Immunology
Shuzhao Li et al.
Editorial Material
Immunology
Stanley A. Plotkin et al.
CLINICAL INFECTIOUS DISEASES
(2012)
Article
Immunology
Kristine L. Bucasas et al.
JOURNAL OF INFECTIOUS DISEASES
(2011)
Article
Immunology
Helder I. Nakaya et al.
Article
Immunology
Troy D. Querec et al.
